Document 0212
 DOCN  M9480212
 TI    Frequent and early HIV-1MN neutralizing capacity in sera from Dutch
       HIV-1 seroconverters is related to antibody reactivity to peptides from
       the gp120 V3 domain.
 DT    9410
 AU    Zwart G; Back NK; Ramautarsing C; Valk M; van der Hoek L; Goudsmit J;
       Department of Virology, University of Amsterdam, The Netherlands.
 SO    AIDS Res Hum Retroviruses. 1994 Mar;10(3):245-51. Unique Identifier :
       AIDSLINE MED/94289062
 AB    The temporal development of HIV-1 neutralizing activity and antibodies
       to the gp120-V3 neutralization domain were studied in sera from 20 Dutch
       HIV-1-infected individuals followed from seroconversion on. Serum
       neutralizing capacity was assessed with three T cell line-tropic
       isolates: HIV-1MN, HIV-1HXB2, and the patient isolate HIV-1(320).
       Neutralizing activity to HIV-1MN developed in 18 individuals (90%)
       within 0 to 10 months after seroconversion. Parallel evolution of IgG
       reactivity to V3 peptides of United States/European type variants, and
       the capability of such peptides to completely inhibit HIV-1MN
       neutralization in four of five tested sera (taken 1-2 years after
       seroconversion), indicate that a large proportion of HIV-1MN
       neutralizing antibodies is directed to V3. The early appearance and high
       frequency of HIV-1MN neutralizing activity in the Dutch study group
       indicate the close relationship of HIV-1MN to HIV-1 variants circulating
       in the Netherlands. Neutralizing activity to HIV-1HXB2 (in 15 of 20
       individuals) developed several months after that to HIV-1MN in all
       individuals (average, 10 months after seroconversion) and was not seen
       in the absence of HIV-1MN neutralizing activity. Neutralizing activity
       to the Dutch isolate HIV-1(320) (found in 11 of 18 tested individuals)
       emerged simultaneously with that to HIV-1MN in 4 individuals but
       appeared later in 7. In most individuals, HIV-1HXB2 neutralization was
       not accompanied by reactivity to a V3 peptide from this strain,
       indicating that the extension of neutralizing activity to more divergent
       strains, which takes place at later stages, must be attributed to
       non-V3-directed antibodies.
 DE    Adult  Amino Acid Sequence  Human  HIV Antibodies/*IMMUNOLOGY  HIV
       Envelope Protein gp120/*IMMUNOLOGY  HIV
       Seropositivity/*BLOOD/MICROBIOLOGY  HIV-1/CLASSIFICATION/*IMMUNOLOGY
       IgG/IMMUNOLOGY  Male  Molecular Sequence Data  Neutralization Tests
       Peptide Fragments/*IMMUNOLOGY  Support, Non-U.S. Gov't  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).